Although GH therapy has a good safety profile in girls with TS, close monitoring of IGF1 levels, abnormal glucose tolerance, reduced insulin sensitivity, benign intracranial hypertension, scoliosis and other skeletal changes at intervals of 3–6 months-is recommended [6, 7]. The gene discussed is IGF1; the disease is scoliosis.